Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis
Gerasimos Konidaris, E. Paul, Andreas Kuznik, et al.
Value in Health (2021) Vol. 24, Iss. 3, pp. 377-387
Open Access | Times Cited: 23

Showing 23 citing articles:

Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer
Xueyan Liang, Xiaoyu Chen, Huijuan Li, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 11
Updates in Management for Local Regionally Advanced Squamous Cell Carcinoma
Norma E. Farrow, Danielle M. Bello
Surgical Clinics of North America (2025)
Closed Access
Immune checkpoint inhibitors for treatment of periorbital squamous cell carcinoma
Jeremy Allan Goldfarb, Renata Ferrarotto, Neil D. Gross, et al.
British Journal of Ophthalmology (2021) Vol. 107, Iss. 3, pp. 320-323
Closed Access | Times Cited: 24
Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer
Xueyan Liang, Xiaoyu Chen, Huijuan Li, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 5
Pembrolizumab vs cemiplimab for the treatment of advanced non-small cell lung cancer with PD-L1 expression levels of at least 50%: A network meta-analysis and cost-effectiveness analysis
Yan Li, Xueyan Liang, Tong Yang, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 8
Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis
Xueyan Liang, Xiaoyu Chen, Huijuan Li, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 4
Cost–Effectiveness of Camrelizumab Plus Chemotherapy in Advanced Squamous Non-Small-Cell Lung Cancer
Xueyan Liang, Xiaoyu Chen, Huijuan Li, et al.
Immunotherapy (2023) Vol. 15, Iss. 14, pp. 1133-1142
Closed Access | Times Cited: 4
Cost-effectiveness analysis of durvalumab, tremelimumab, and etoposide-platinum in first-line treatment of extensive-stage small cell lung cancer
Mingyu Meng, Xiaoxia Liu, Xueyan Liang, et al.
Medicine (2024) Vol. 103, Iss. 16, pp. e37836-e37836
Open Access | Times Cited: 1
Cost-effectiveness of additional serplulimab to chemotherapy in metastatic squamous non-small cell lung cancer patients
Hanrui Zheng, Ya Zeng, Feng Wen, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50%
Liting Wang, Peng Ye, Xiaohui Zeng, et al.
Advances in Therapy (2021) Vol. 38, Iss. 8, pp. 4354-4365
Closed Access | Times Cited: 10
Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma
E. Paul, Gerasimos Konidaris, Shannon Cope, et al.
Journal of Managed Care & Specialty Pharmacy (2021) Vol. 27, Iss. 11, pp. 1513-1525
Open Access | Times Cited: 6
Cemiplimab in advanced cutaneous squamous cell carcinoma
Piyu Parth Naik
Dermatologic Therapy (2021) Vol. 34, Iss. 6
Open Access | Times Cited: 6
Nivolumab plus ipilimumab versus the EXTREME regimen in recurrent/metastatic squamous cell carcinoma of the head and neck: a cost-effectiveness analysis
Dongmei Ye, Xueyan Liang, Xiaoyu Chen, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
First-line serplulimab plus chemotherapy versus chemotherapy in PD-L1-positive esophageal squamous-cell carcinoma: a cost-effectiveness analysis
Xueyan Liang, Mingyu Meng, Shiran Qin, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Cost‑effectiveness analysis of tislelizumab plus chemotherapy in Chinese patients with advanced or metastatic oesophageal squamous cell carcinoma
Li Zhang, Henghai Su, Xueyan Liang, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Cost-effectiveness of cemiplimab plus chemotherapy versus chemotherapy for the treatment of advanced non-small cell lung cancer
Xueyan Liang, Xiaoyu Chen, Huijuan Li, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 1
Clinicopathological characteristics and clinical morbidity in high‐risk head and neck cutaneous squamous cell carcinoma patients in Western Australia
Piyush Grover, Stephanie Flukes, Angela Jacques, et al.
Internal Medicine Journal (2021) Vol. 52, Iss. 6, pp. 944-951
Open Access | Times Cited: 3
Recent Trends in the Integrated Management of Cutaneous Squamous Cell Carcinoma
Piyu Parth Naik
Dermato (2022) Vol. 2, Iss. 3, pp. 59-72
Open Access | Times Cited: 1
Electrochemotherapy vs radiotherapy in the treatment of primary cutaneous malignancies or cutaneous metastases from primary solid organ malignancies: A systematic review and narrative synthesis
Angus T. McMillan, Luke McElroy, L. O’Toole, et al.
European Journal of Surgical Oncology (2023) Vol. 49, Iss. 2, pp. e149-e149
Open Access
Electrochemotherapy vs radiotherapy in the treatment of primary cutaneous malignancies or cutaneous metastases from primary solid organ malignancies: A systematic review and narrative synthesis
A. McMillan, Luke McElroy, L. O’Toole, et al.
PLoS ONE (2023) Vol. 18, Iss. 7, pp. e0288251-e0288251
Open Access
Nonmelanoma Skin Cancers
ChrysalyneD. Schmults, DanielleA. Parker
(2023), pp. 477-496
Closed Access
Recent Developments in the Management of Orbital and Periocular Neoplasms
Jeremy Allan Goldfarb, Bita Esmaeli
Springer eBooks (2022), pp. 311-325
Closed Access
Cemiplimab for advanced cutaneous squamous cell carcinoma: survival gains at acceptable cost

PharmacoEconomics & Outcomes News (2021) Vol. 871, Iss. 1, pp. 7-7
Closed Access
Page 1

Scroll to top